AU612575B2 - Interleukin-2 induced antineoplastic peptide - Google Patents

Interleukin-2 induced antineoplastic peptide Download PDF

Info

Publication number
AU612575B2
AU612575B2 AU73780/87A AU7378087A AU612575B2 AU 612575 B2 AU612575 B2 AU 612575B2 AU 73780/87 A AU73780/87 A AU 73780/87A AU 7378087 A AU7378087 A AU 7378087A AU 612575 B2 AU612575 B2 AU 612575B2
Authority
AU
Australia
Prior art keywords
cells
antineoplastin
inhibiting
proliferation
neoplastic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU73780/87A
Other languages
English (en)
Other versions
AU7378087A (en
Inventor
Ingegerd Hellstrom
Karl Erik Hellstrom
Daniel R. Twardzik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU7378087A publication Critical patent/AU7378087A/en
Application granted granted Critical
Publication of AU612575B2 publication Critical patent/AU612575B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4718—Cytokine-induced proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/91—Cell lines ; Processes using cell lines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU73780/87A 1986-06-04 1987-06-03 Interleukin-2 induced antineoplastic peptide Ceased AU612575B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87044086A 1986-06-04 1986-06-04
US870440 1986-06-04

Publications (2)

Publication Number Publication Date
AU7378087A AU7378087A (en) 1987-12-10
AU612575B2 true AU612575B2 (en) 1991-07-18

Family

ID=25355375

Family Applications (1)

Application Number Title Priority Date Filing Date
AU73780/87A Ceased AU612575B2 (en) 1986-06-04 1987-06-03 Interleukin-2 induced antineoplastic peptide

Country Status (9)

Country Link
EP (1) EP0248642B1 (el)
JP (1) JPS6322100A (el)
AT (1) ATE81591T1 (el)
AU (1) AU612575B2 (el)
CA (1) CA1320906C (el)
DE (1) DE3782276T2 (el)
ES (1) ES2052562T3 (el)
GR (1) GR3006212T3 (el)
IL (1) IL82734A (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1196958B (it) * 1986-07-10 1988-11-25 Ellem Ind Farmaceutica Derivato di timo attivo per via orale, procedimenti per la sua preparazione e relative composizioni farmaceutiche
AU609128B2 (en) * 1987-04-02 1991-04-26 Amrad Operations Pty. Limited Leukaemia-inhibitory factor
MY197176A (en) 2018-02-01 2023-05-30 Nkmax Co Ltd Method of producing natural killer cells and composition for treating cancer

Also Published As

Publication number Publication date
CA1320906C (en) 1993-08-03
DE3782276T2 (de) 1993-03-04
EP0248642A2 (en) 1987-12-09
ES2052562T3 (es) 1994-07-16
DE3782276D1 (de) 1992-11-26
IL82734A (en) 1992-05-25
EP0248642A3 (en) 1989-11-02
ATE81591T1 (de) 1992-11-15
EP0248642B1 (en) 1992-10-21
JPS6322100A (ja) 1988-01-29
GR3006212T3 (el) 1993-06-21
IL82734A0 (en) 1987-12-20
AU7378087A (en) 1987-12-10

Similar Documents

Publication Publication Date Title
Ferreira et al. Activity of various fractions of bradykinin potentiating factor against angiotensin I converting enzyme
US6825166B2 (en) Molecular conjugates for use in treatment of cancer
JPS58157723A (ja) インタ−ロイキン２を含有してなる免疫療法剤
Alford et al. Delayed cutaneous hypersensitivity reactions to extracts of malignant and normal breast cells.
CA2186423C (en) Protein which induces interferon-gamma production by immunocompetent cell
Balcewicz-Sablinska et al. Human eosinophil cytotoxicity-enhancing factor. II. Multiple forms synthesized by U937 cells and their relationship to thioredoxin/adult T cell leukemia-derived factor.
EP2189470A1 (en) Tumor antigens
US5393534A (en) Liver-derived tumor cell growth inhibitor
AU612575B2 (en) Interleukin-2 induced antineoplastic peptide
JP2001525337A (ja) 前立腺癌の治療に有効なコンジュゲート
JP4914350B2 (ja) セラリシン（Ｓｅｒｒａｌｉｓｉｎｓ）のポリペプチド断片を含む医薬組成物
US5580561A (en) Methods and pharmaceutical compositions for blocking suppression of immune defense mechanisms using an antibody, a factor, or an antisense peptide
Park et al. Isolation and characterization of lectins from stem and leaves of Korean mistletoe (Viscum album var. coloratum) by affinity chromatography
RU2593003C2 (ru) Препарат экзосом - онкосом и способ иммунотерапии солидных опухолей с его использованием
AU601168B2 (en) Novel cell growth regulatory factor
RU2205010C2 (ru) Природные противоопухолевые или противовирусные вещества и их применение
EP0086475A2 (en) A method of manufacturing anti-tumor substances
CN112979640B (zh) 一类生物碱二聚体类化合物及其在制备pd-1/pd-l1通路抑制剂中的应用
IE861095L (en) Preparing recombinant interferon
US4752578A (en) Collagenase inducing factor
RU2283129C1 (ru) Белковопептидный противоопухолевый композит, клеточный препарат, активированный этим композитом, и способ профилактики или лечения опухолей
GB1590457A (en) Thymosin a1
Wang et al. Antitumor effects of the molecule-downsized immunoconjugate composed of lidamycin and Fab’fragment of monoclonal antibody directed against type IV collagenase
CN111732633B (zh) 一种抗肿瘤多肽和在制备抗肿瘤药物方面的用途
CN111732631B (zh) 一种多肽及其在制备治疗和预防肿瘤的药物中的应用